CANDEL THERAPEUTICS, INC. Impairment of Long-Lived Assets Held-for-use
CANDEL THERAPEUTICS, INC. (CADL) reported Impairment of Long-Lived Assets Held-for-use of $90.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-12
- CANDEL THERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2023-12-31 was $400.00K.
- CANDEL THERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2023-09-30 was $400.00K.
- CANDEL THERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2021-12-31 was $600.00K.
- CANDEL THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2025 was $90.00K, a 119.51% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $41.00K, a 89.75% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $400.00K.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 3 month as first filed | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2025-12-31 | $90.00K 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $41.00K 10-K · filed 2026-03-12 | |||
| 2023-12-31 | $400.00K 10-K · filed 2024-03-28 | $800.00K derived: sum of 2 quarters · filed 2024-03-28 | $400.00K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $400.00K 10-K · filed 2024-03-28 | $200.00K 10-Q · filed 2023-11-09 | ||
| 2021-12-31 | $600.00K 10-K · filed 2023-03-30 | $553.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |